natgillin/translations-raw huggingface dataset:
Undersøgelse af PD-patienter i mellemfasen eller den afsluttende fase
Studies in mid- to late-stage PD patients
Undersøgelse af serologisk status anbefales også ved administration af yderligere vaccinedoser, hvis sådanne er nødvendige (dvs. afhængig af patientens serologiske status) med henblik på kort- og langsigtet beskyttelse.
Serologic testing is also recommended, with the administration of subsequent doses of vaccine, if necessary, (i.e according to the serologic status of the patient) for short and long term protection.
Undersøgelse af serologisk status anbefales også ved administration af yderligere vaccinedoser, hvis sådanne er nødvendige (dvs. afhængig af patientens serologiske status) med henblik på kort- og langsigtet beskyttelse.
Serologic testing is also recommended, with the administration of subsequent doses of vaccine, if necessary, (i.e. according to the serologic status of the patient) for short and long term protection.
Undersøgelse af sitagliptin i kombination med metformin og en PPAR-agonist
Study of sitagliptin in combination with metformin and a PPAR agonist
Undersøgelse af sitagliptin i kombination med metformin og et sulfonylurinstof
Study of sitagliptin in combination with metformin and a sulphonylurea
Undersøgelse af sitagliptin i kombination med metformin og insulin
Study of sitagliptin in combination with metformin and insulin
Undersøgelse af tænderne sammen med forebyggende tandbehandling og en individuel vurdering af fordele kontra risici anbefales inden behandling med Prolia hos patienter med samtidige risikofaktorer.
A dental examination with preventive dentistry and an individual benefit- risk assessment is recommended prior to treatment with Prolia in patients with concomitant risk factors.
Undersøgelse af tænderne sammen med forebyggende tandbehandling og en individuel vurdering af fordele kontra risici anbefales inden behandling med XGEVA.
A dental examination with preventive dentistry and an individual benefit- risk assessment is recommended prior to treatment with XGEVA.
Undersøgelse CAC-002-01, (en åben, urandomiseret enkeltcenter-fortsættelsesundersøgelse af cholsyre-kapsler hos patienter med medfødte fejl i galdesyresyntesen) var fortsættelsen af undersøgelse CAC-91-10-10 og begyndte den 1. januar 2010.
Study CAC-002-01, (An open-label, single-centre, nonrandomized continuation study of cholic acid capsules in subjects with inborn errors of bile acid synthesis), was the continuation of study CAC-91- 10-10 and started on 1 Jan 2010.
Undersøgelse før behandlingen startes
Examinations before starting treatment
Undersøgelse I: Daglig ON tid (timer)
Study I: Daily On time (h)
Undersøgelse II: Daglig ON tid (%)
Study II: Proportion of daily On time (%)
Undersøgelse med historisk kontrolgruppe (25 mg/kg/dag)
Historically Controlled Trial (25mg/kg/day)
Undersøgelse NB-302 havde et mere intensiv adfærdsmodifikationsprogram, mens undersøgelse NB-303s primære endpoint var ved uge 28 for at tillade re-randomisering til forskellige doser i den sidste del af undersøgelsen.
Study NB-302 had a more intensive behavioural modification program, while the primary endpoint of Study NB-303 was at Week 28 to allow for re-randomization to different doses in the latter portion of the study.
Undersøgelse NB-302 havde et mere intensivt adfærdsmodifikationsprogram, mens undersøgelse NB-303s primære endpoint var ved uge 28 for at tillade re- randomisering til forskellige doser i den sidste del af undersøgelsen.
Study NB-302 had a more intensive behavioural modification program, while the primary endpoint of Study NB-303 was at Week 28 to allow for re-randomization to different doses in the latter portion of the study.
undersøgelse, der vurderer effekten af naltrexon (depot) / bupropion (depot) vedr.
release (ER) /bupropion ER on the occurrence of major adverse cardiovascular
Undersøgelsen af børn i alderen to til 18 år viste, at Isentress er sikkert til anvendelse hos børn, og at mængden af lægemidlet i børnenes blod svarer til den hos voksne.
The study in children between 2 and 18 years showed that Isentress was safe in children and levels of the medicine obtained in the blood in children were similar to those obtained in adults.
Undersøgelsen af børn viste også en lignende virkning med kombinationen af Pegasys og ribavirin som den, der sås hos voksne for kombinationen af Pegasys og ribavirin.
The study in children showed similar effectiveness with the combination of Pegasys and ribavirin to that seen in adults treated with Pegasys and ribavirin.
Undersøgelsen af Extavia hos patienter med en enkelt demyeliniserende hændelse omfattede 487 patienter, som fik enten Extavia eller placebo i to år.
The study of Extavia in patients with a single demyelinating event involved 487 patients, who received either Extavia or placebo for two years.
Undersøgelsen af patienter med kronisk nyreinsufficiens viste, at Abseamed var sikkert og effektivt, når det blev givet under huden.
The study in patients with chronic kidney failure showed that Abseamed was safe and effective when given under the skin.
Undersøgelsen af patienter med kronisk nyreinsufficiens viste, at Binocrit var sikkert og effektivt, når det blev givet under huden.
The study in patients with chronic kidney failure showed that Binocrit was safe and effective when given under the skin.
Undersøgelsen af patienter med kronisk nyreinsufficiens viste, at Epoetin Alfa Hexal var sikkert og effektivt, når det blev givet under huden.
The study in patients with chronic kidney failure showed that Epoetin Alfa Hexal was safe and effective when given under the skin.
Undersøgelsen af patienter, der fik kemoterapi, viste, at Abseamed også var lige så effektivt som Eprex/Erypo, når det blev injiceret under huden.
The study in patients receiving chemotherapy showed that Abseamed was also as effective as Eprex/Erypo when it was injected under the skin.
Undersøgelsen af patienter, der fik kemoterapi, viste, at Binocrit også var lige så effektivt som Eprex/Erypo, når det blev injiceret under huden.
The study in patients receiving chemotherapy showed that Binocrit was also as effective as Eprex/Erypo when it was injected under the skin.
Undersøgelsen af patienter, der fik kemoterapi, viste, at Epoetin Alfa Hexal også var lige så effektivt som Eprex/Erypo, når det blev injiceret under huden.
The study in patients receiving chemotherapy showed that Epoetin Alfa Hexal was also as effective as Eprex/Erypo when it was injected under the skin.
Undersøgelsen af raske mennesker viste, at saxagliptin, når det tages i doser på 2,5 mg to gange dagligt, medfører de samme niveauer af aktive stoffer i blodet over en periode på 24 timer, som når det tages i en dosis på 5 mg en gang om dagen.
The study in healthy people showed that when saxagliptin is taken at 2.5 mg twice daily it produces the same levels of active substance in the blood over a 24 hour period as when it is taken at 5 mg once daily.
Undersøgelsen blev afbrudt på et tidligt stadium, da der forekom en række svære kardiovaskulære hændelser (såsom kardiovaskulært dødsfald eller hospitalsindlæggelse og slagtilfælde) hos nogle af de patienter, som fik Multaq.
The study was stopped early because of the occurrence of severe cardiovascular events (such as cardiovascular death or hospitalisation and stroke) in some patients taking Multaq.
Undersøgelsen blev derefter forlænget til fire år.
The study was then extended to four years.
Undersøgelsen blev forlænget for at påvise virkningerne af at give en boosterdosis af Bexsero ved 12- månedersalderen eller senere til børn, som allerede havde fået Bexsero som ganske små, sammenholdt med at give to "indhentningsdoser" til dem, der ikke havde fået Bexsero.
This study was extended to look at the effects of giving a booster dose of Bexsero at or after 12 months of age to children who had already received Bexsero in early infancy, compared with giving two ‘catch-up’ doses to those who had not.
Undersøgelsen blev gennemført med henblik på at vise, at Omnitrope er sammenligneligt med referencelægemidlet, Genotropin.
Omnitrope was studied to show that it is comparable to the reference medicine, Genotropin.
Undersøgelsen har til formål at undersøge virkningen af Fampyra med hensyn til andre aspekter af gangevnen ud over ganghastigheden og vil yderligere undersøge metoder til tidligere identifikation af patienter, som responderer tidligere på Fampyra, for at vejlede om yderligere behandling.
The study will look at the effects of Fampyra on other aspects of walking ability besides walking speed and will further investigate ways for the earlier identification of patients who respond to Fampyra earlier in order to guide further treatment.
Undersøgelsen hos børn gav tilsvarende resultater.
Similar results were seen in the study in children.
Undersøgelsen hos patienter i kemoterapi viste, at Silapo gav de samme forbedringer i hæmoglobinniveauet som dem, der er beskrevet i den videnskabelige litteratur for andre epoetiner.
The study in patients receiving chemotherapy showed that Silapo brought about similar improvements in haemoglobin levels as those reported in the scientific literature for other epoetins.
Undersøgelsen hos patienter med moderat nedsat nyrefunktion viste, at virkningerne af Invokana var nedsat hos disse patienter, men stadig klinisk relevant: I forhold til placebo var nedsættelsen af HbA1c 0,30 % ved en dosis på 100 mg.
The study in patients with moderately reduced kidney function showed that the effects of Invokana were reduced in these patients, but still clinically relevant: the reduction of HbA1c levels compared with placebo was 0.30% with the 100 mg dose.
Undersøgelsen hos unge viste, at det er nødvendigt med to doser for at opnå en tilstrækkelig immunrespons.
The study in adolescents found that two doses were needed to produce an adequate immune response.
Undersøgelsen hos ældre patienter viste, at Invokana også havde klinisk relevante virkninger hos patienter over 75 år, hos hvem der opnåedes en reduktion af HbA1c i forhold til placebo på 0,70 % og 0,57 % ved en dosis på henholdsvis 300 mg og 100 mg.
The study in older patients showed that Invokana had clinically relevant effects also in patients above 75 years of age with HbA1c reductions compared with placebo of 0.70% and 0.57% with the 300 mg and 100 mg doses, respectively.
Undersøgelsen konkluderede, at levetiracetam ikke adskilte sig fra placebo (non- inferiort) i forhold til ændring fra baseline med hensyn til Leiter-R Opmærksomhed og Hukommelse, Hukommelsesscreening samlede score per-protokol population.
It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population.
Undersøgelsen omfattede 16 mænd (55 %) og 13 kvinder (45 %) med en gennemsnitsalder på 30,7 år og en variationsbredde på 18- 55 år.
Sixteen males (55%) and 13 females (45%) were included with a mean age of 30.7 years, ranging from 18 to 55 years.
Undersøgelsen omfattede 16 mænd (55 %) og 13 kvinder (45 %) med en gennemsnitsalder på 30,7 år og en variationsbredde på 18-55 år.
Sixteen males (55%) and 13 females (45%) were included with a mean age of 30.7 years, ranging from 18 to 55 years.
Undersøgelsen omfattede 343 patienter med ALK-positiv ikke-småcellet lungekræft og sammenlignede Xalkori med andre kræftlægemidler (pemetrexed med enten cisplatin eller carboplatin).
The study involved 343 patients with ALK-positive NSCLC and compared Xalkori with other cancer medicines (pemetrexed with either cisplatin or carboplatin).
Undersøgelsen omfattede 347 patienter med ALK-positiv ikke-småcellet lungekræft og sammenlignede Xalkori med 1 af 2 kræftlægemidler (enten pemetrexed eller docetaxel).
The study involved 347 patients with ALK-positive NSCLC and compared Xalkori with 1 of 2 cancer medicines (either pemetrexed or docetaxel).
Undersøgelsen omfattede 39 patienter på over seks år og sammenlignede Kalydeco med placebo.
The study involved 39 patients over 6 years of age and compared Kalydeco with placebo.
Undersøgelsen omfattede 69 patienter i alderen seks år og derover.
The study included 69 patients aged 6 years and above.
Undersøgelsen omfattede både patienter, hvis kræftceller producerede et højt antal PD-L1, og patienter, hvis kræftceller producerede et lavt antal PD-L1.
The study included patients whose cancer cells produced high levels of PD-L1 as well as patients whose cancer cells produced low levels of PD-L1.
Undersøgelsen omfattede kvinder i alderen 55 til 80 år, som var mindst 5 år postmenopausale, havde et lumbal BMD på 2 til 5 SD under den præmenopausale middelværdi (T- score) i mindst én ryghvirvel [L1-L4], og som havde haft 1-4 tidligere vertebrale frakturer.
The study enrolled women aged 55 to 80 years, who were at least 5 years postmenopausal, who had a BMD at lumbar spine of 2 to 5 SD below the premenopausal mean (T-score) in at least one vertebra [L1-L4], and who had one to four prevalent vertebral fractures.
Undersøgelsen omfattede mere end 2 000 voksne med kræft, som fik deres første behandling med kemoterapi indeholdende cisplatin.
The study involved over 2,000 adults with cancer who were receiving their first course of chemotherapy including cisplatin.
Undersøgelsen omfattede patienter med nyreinsufficiens klassificeret på basis af kreatinin-clearance som let (50 til <80 ml/min), moderat (30 til <50 ml/min) og svær (<30 ml/min) samt patienter med ESRD i hæmodialyse.
The study included patients with renal impairment classified on the basis of creatinine clearance as mild (50 to < 80 ml/min), moderate (30 to < 50 ml/min), and severe (< 30 ml/min), as well as patients with end-stage renal disease (ESRD) on haemodialysis.
Undersøgelsen omfattede patienter med nyreinsufficiens klassificeret på basis af kreatinin-clearance som let (50 til <80 ml/min), moderat (30 til <50 ml/min) og svær (<30 ml/min) samt patienter med ESRD i hæmodilayse.
The study included patients with renal impairment classified on the basis of creatinine clearance as mild (50 to < 80 ml/min), moderate (30 to < 50 ml/min), and severe (< 30 ml/min), as well as patients with end-stage renal disease (ESRD) on haemodialysis.
Undersøgelsen omfattede patienter med nyreinsufficiens klassificeret på basis af kreatinin-clearance som mild (50 til <80 ml/min), moderat (30 til <50 ml/min) og svær (<30 ml/min) samt patienter med ESRD i hæmodialyse.
The study included patients with renal impairment classified on the basis of creatinine clearance as mild (50 to < 80 ml/min), moderate (30 to < 50 ml/min), and severe (< 30 ml/min), as well as patients with end-stage renal disease (ESRD) on haemodialysis.
Undersøgelsen omfattede patienter over 65 år og yngre patienter, der ikke kunne behandles med højdosis-kemoterapi.
The study included patients over 65 years of age, as well as younger patients who could not be treated with high-dose chemotherapy.
Undersøgelsen sammenlignede Imnovid plus lavdosis dexamethason med højdosis dexamethason alene.
The study compared Imnovid plus low-dose dexamethasone with high-dose dexamethasone alone.
Undersøgelsen sammenlignede virkningen af at skifte til Atripla-tabletter, indtaget på tom mave, med virkningen af at fortsætte den effektive hiv-behandlingskombination.
The study compared the effectiveness of switching to Atripla tablets, taken on an empty stomach, with that of remaining on the successful HIV treatment combination.
Undersøgelsen sammenligner risikoen ved brug af nomegestrol/estradiol med risikoen ved brug af kombinerede orale præventionsmidler, der indeholder levonorgestrel.
This study compares the risk of nomegestrol/estradiol use with the risk of levonorgestrel-containing combined oral contraceptive use.
Undersøgelsen skal desuden give oplysninger om graviditeter hos kvinder, der tager lægemidlet, og om lægernes overholdelse af anbefalingerne om at screene og overvåge patienterne før og under behandlingen.
The study will also provide data on pregnancies in women taking the medicine, and on healthcare professionals’ compliance with the recommendations to screen and monitor patients before and during treatment.
Undersøgelsen skal omfatte test af serumelektrolytter og ketoner, blodglucose og – hvis det er indiceret – blodets pH-værdi samt laktat-, pyruvat- og metforminværdier.
Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate and metformin levels.
Undersøgelsen så navnlig på lægemidlets sikkerhed, men målte også dets evne til at reducere GAG- niveauet i urinen og leverens størrelse.
The study was looking mainly at the safety of the medicine, but it also measured its ability to reduce the levels of GAGs in the urine and the size of the liver.
Undersøgelsen så nærmere på kropsvægten og klorindholdet i sved, som begge er lave hos patienter med cystisk fibrose.
The study looked at bodyweight and the amount of chloride in sweat, both of which are reduced in patients with cystic fibrosis.
Undersøgelsen så også på en forlængelsesfase, hvor alle patienter modtog Revolade.
The study had also an extension phase, in which all patients received Revolade.
Undersøgelsen så primært på den procentdel af patienter, der responderede på behandlingen.
This study also looked mainly at the percentage of patients who responded to treatment.
Undersøgelsen så på varigheden af svær neutropeni i løbet af patienternes første cytotoksiske kemoterapicyklus.
The study looked at the duration of severe neutropenia during the patients’ first cycle of cytotoxic chemotherapy.
Undersøgelsen var ”åben”, hvilket betyder, at lægen og patienterne vidste, hvilke lægemidler patienterne fik, fordi Ferriprox blev taget gennem munden, hvorimod deferoxamin blev taget som injektion under huden i løbet af natten.
The study was ‘open label’, meaning that the doctor and patients knew which medicine they were using, because Ferriprox was given by mouth, whereas deferoxamine was given by injection under the skin overnight.
Undersøgelsen varede 12 måneder, og man målte børnenes højde ved begyndelsen og afslutningen på undersøgelsen samt væksthastigheden i løbet af undersøgelsen.
The study lasted 12 months, and measured the children’s height at the beginning and the end of the study, and the speed of growth during the study.
Undersøgelsen varede i 20 uger og bestod af en startfase på 8 uger til fastlæggelse af dosis og en evalueringsfase på 12 uger.
The study, which lasted for 20 weeks, consisted of an initial phase of 8 weeks to establish the dose and an evaluation phase of 12 weeks.
Undersøgelsen ved hjerteorm viste, at Nexgard Spectra forebyggede infektion med hjerteorm, da alle de testede hunde var negative seks måneder efter sidste behandling.
The heartworm field study showed that Nexgard Spectra prevented heartworm infection as all dogs tested negative six months after the last treatment.
Undersøgelsen vedrørende CAPS viste en betydelig og hurtig forbedring af symptomerne, idet den gennemsnitlige symptomscore faldt fra 4,5 til 0,8 i løbet af de første tre dage efter behandlingens start.
The study in CAPS showed a significant and rapid improvement in symptoms, with a fall in average symptom score from 4.5 to 0.8 within 3 days of starting treatment.
Undersøgelsen vedrørte PET- scanningernes følsomhed og deres specificitet (dvs. hvor sikkert de var i stand til at skelne forsøgspersoner med betydelig plakdannelse i hjernen fra personer uden plak).
The study looked at sensitivity and specificity of the PET scans (how well they identified volunteers with plaques in the brain and how accurate they were in distinguishing them from those who did not).
Undersøgelsen vil løbende blive
The study protocol, including
Undersøgelsen viste desuden en reduktion på over 90 % i tegn på overfølsomhed for loppebid (loppebetinget allergisk dermatitis) hos hunde, der blev behandlet enten med Vectra 3D eller sammenligningsproduktet.
The study also showed a reduction of over 90% in the signs of flea allergy dermatitis in dogs treated with either Vectra 3D or the comparator product.
Undersøgelsen viste desuden, at de patienter, der fik Keytruda, levede længere end de, der fik ipilimumab.
The study also found that patients treated with Keytruda lived longer than patients who received ipilimumab.
Undersøgelsen viste desuden, at Vectra Felis var effektivt som supplerende behandling af overfølsomhed for loppebid hos katte.
The study also showed that Vectra Felis was effective as an aid in the treatment of flea allergy dermatitis in cats.
Undersøgelsen viste en gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis” for Clinician's interview based impression of change (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; SIB: p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p = 0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p = 0.003; severe impairment battery (SIB): p = 0.002).
Undersøgelsen viste en gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis” for Clinician's interview based impression of change (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; SIB: p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste en gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis” for Clinician's interview based impression of change (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; SIB: p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician’s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer’s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Undersøgelsen viste et fald i antallet af indlæggelser på grund af hjerte-kar-problemer, særligt i relation til atrieflimren.
The study showed a reduction in the number of cardiovascular events leading to hospitalisations particularly those related to atrial fibrillations.
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis for the Clinician´s interview based impression of change” (CIBIC-plus): p = 0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p = 0,003; severe impairment battery (SIB): p = 0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p = 0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p = 0.003; severe impairment battery (SIB): p = 0.002).
Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (”observed cases analysis for the Clinician´s interview based impression of change” (CIBIC-plus): p=0,025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0,003; Severe impairment battery (SIB): p=0,002).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).